It has been demonstrated that ARV-825, which combines a BRD4 inhibitor with a cereblon ligand using PROTAC technology, showed to be more effectively breaking down BRD4, inhibiting tumor growth effectively and consistently [12]. Here, BRD4 is linked to neoplasm.